Cevian at 19.4%, Three Downgrades: Pearson Reports Today

PSO reports its 2026 interim results this morning against a backdrop of rising short interest, an activist stake that keeps growing, and a run of analyst downgrades from firms that were positive on the stock as recently as January.

The most consequential ownership fact is Cevian Capital's 19.4% stake, up from 19.17% in its previous Schedule 13D/A filing on 23 September. Cevian has now filed seven times since first crossing the 5% threshold in April 2025, and each amendment has nudged the position higher. That level of concentrated, active ownership places the activist in a position to press for operational or capital-allocation changes, and the steady accumulation tells its own story about where Cevian thinks the stock is going. Stakes are as last disclosed; positions around the 5% threshold can change without triggering a new filing, but at 19.4% any material move will require disclosure. Artisan Partners holds another 12% and BlackRock 8.6%, leaving the three largest holders controlling more than 40% of the company between them.

Analyst opinion has moved in the opposite direction. Three bellwether downgrades have landed since July: JP Morgan cut to Neutral from Overweight in July, Citigroup followed to Neutral from Buy in September, and UBS moved to Neutral from Buy on 8 October, just two weeks ago. None of the three published a new price target alongside their action, which makes it harder to read exactly where the Street thinks fair value sits. The consensus rating in the data carries a mean target of $10.25, but that figure is dated to late 2020 and cannot be reconciled with a $18.39 share price; it should be treated as stale. What is clear is the direction: three firms that were constructive have now stepped back to the sidelines within four months of each other, suggesting a shared concern about near-term catalysts rather than any fundamental reassessment.

Short interest has climbed roughly 70% over the past month in absolute share terms, reaching around 4.4 million shares on 21 October. That said, the lending market is not particularly stressed: cost to borrow is under 1%, and availability is at 55.7%, meaning there is still meaningful room in the lending pool relative to what has already been borrowed. The ORTEX short score of 55.5 is mid-range and has barely shifted over the past two weeks, suggesting this is a deliberate build rather than a squeeze-driven event. The stock itself has recovered strongly, up 15.7% over the past month to $18.39, which may explain why short sellers are testing the rally rather than chasing it.

The last comparable print, July's interim update, pushed the ADR down 3.7% on the day and 5.5% over the following week. The earlier July 2026 event saw a 7.1% gain on the day. The split reaction history means the market has no settled expectation for which way Pearson moves on results day. Today's print is therefore a direct test of whether the Cevian-backed transformation thesis can withstand a Street that has just moved three houses from Buy to Neutral in quick succession.